top of page

UCB’s Bimekizumab to reshape psoriasis market

  • Writer: Laurent DECORY
    Laurent DECORY
  • Dec 12, 2020
  • 1 min read

The $ 20+ billion Psoriasis treatment market has been dominated by AbbVie's Humira.

But things might change soon.

After beating J&J’s Stelara and AbbVie’s Humira, UCB’s Bimekizumab now wins over Novartis’s Cosentyx, with potential to reshape busy psoriasis market.




Comments


bottom of page